Ronald Soucier, DO
Internal Medicine · Egg Harbor Township, NJNPI 1184667693
Payments from drug & device makers
Across 221 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$543
- Lilly USA, LLC$430
- Astellas Pharma US Inc$248
- Bayer$227
- Pfizer$203
- plus $949 from 19 others
What the payments were for
- Food & beverage$4,300100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,700 |
| AstraZeneca(2 entities) | 23 | $543 |
| Lilly USA, LLC | 27 | $430 |
| Astellas Pharma US Inc | 14 | $248 |
| Bayer | 10 | $227 |
| Pfizer | 13 | $203 |
| Amgen | 9 | $140 |
| Boehringer Ingelheim | 8 | $134 |
| Daiichi Sankyo Inc. | 7 | $107 |
| Exact Sciences | 4 | $98 |
| Johnson & Johnson | 1 | $97 |
| Agios Pharmaceuticals, Inc. | 4 | $81 |
| Optinose US, Inc. | 3 | $53 |
| Lundbeck LLC | 2 | $37 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| GSK | 2 | $27 |
| Abbott | 1 | $19 |
| AbbVie | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Averitas Pharma Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,300 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $199,958 |
| RybelsusSemaglutide | 40 | $81,258 |
| EliquisApixaban | 60 | $64,585 |
| JardianceEmpagliflozin | 39 | $64,573 |
| JanuviaSitagliptin Phosphate | 58 | $62,023 |
| FarxigaDapagliflozin Propanediol | 46 | $47,756 |
| WegovySemaglutide | 22 | $42,931 |
| XareltoRivaroxaban | 18 | $29,379 |
| MounjaroTirzepatide | 17 | $27,673 |
| TradjentaLinagliptin | 25 | $23,783 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 22 | $19,017 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $15,692 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $12,818 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $12,162 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,700 | $324,146198 claims |
| MerckJanuvia, Janumet Xr, Janumet | $15 | $96,73394 claims |
| Boehringer IngelheimJardiance, Tradjenta | $134 | $88,35664 claims |
| PfizerEliquis | $203 | $64,58560 claims |
| AstraZenecaFarxiga | $543 | $47,75646 claims |
| Johnson & JohnsonXarelto | $97 | $29,37918 claims |
| Lilly USA, LLCMounjaro | $430 | $27,67317 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $27 | $20,94729 claims |
| AbbVieSynthroid | $19 | $4,63767 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Egg Harbor Township
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.